Canadian guidelines for the management of adult growth hormone deficiency

Clinical and Investigative Medicine

Volumn 29, Issue 2, 2006, Pages 83-90

  Ur, Ehud ^a,e   Serri, Omar ^b   Legg, Karen ^a   Murphy, Liam J ^c   Ezzat, Shereen ^d  

^a DALHOUSIE UNIVERSITY   (Canada)

^b NOTRE DAME HOSPITAL   (Canada)

^c UNIVERSITY OF MANITOBA   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

^e QUEEN ELIZABETH II HEALTH SCIENCES CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; CLONIDINE; GLUCAGON; GROWTH HORMONE; GROWTH HORMONE RELEASING FACTOR; INSULIN; LEVODOPA;

CANADA; CARPAL TUNNEL SYNDROME; CLINICAL FEATURE; DIAGNOSTIC TEST; DOSE RESPONSE; DRUG HALF LIFE; DRUG WITHDRAWAL; EDEMA; FLUSHING; FOLLOW UP; GLUCOSE INTOLERANCE; GROWTH HORMONE DEFICIENCY; HEADACHE; HEART PALPITATION; HORMONE SUBSTITUTION; HUMAN; HYPOGLYCEMIA; HYPOTENSION; INSULIN RESISTANCE; MEDICAL PRACTICE; MEDICAL SPECIALIST; NAUSEA; NEUROENDOCRINE DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; NURSE; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; PROVOCATION TEST; REVIEW; SIDE EFFECT; SWEATING; TITRIMETRY; TREMOR;

EID: 33646241506     PISSN: 0147958X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (33)

1. Harman, SM, Blackman MR. Use of growth hormone for prevention of treatment of effects of aging. J Gerontol A Biol Sci Med Sci. 2004;59:652-8.
2. Regal M, Paramo C, Sierra SM, Garcia-Mayor RV. Prevalence and incidence of hypopituitarism in an adult Caucasian population in northwestern Spain. Clin Endocrinol 2001;55:735-40.
3. Wuster C, Slenezka E, Ziegler R. Increased prevalence of osteoporosis and atherosclerosis in patients with conventionally substituted pituitary insufficiency: is there need for additional growth hormone substitution? Klin Wochernschr 1991;69:769-73.
4. Pfeifer M, Cerhovec R, Zizek B, Prezelj J, Poredos P, Clayton RN. Growth hormone (GH) treatment reverses early atherosclerotic changes in GH-deficiency adults. J Clin Endocrinol Metab 1999;84:453-7.
5. Caroll PV, Christ ER, Bengtsson BA et al. Growth hormone deficiency in adulthood and the effects of growth hormone replacement: a review. J Clin Endocrinol Metab 1998;83:382-95.
6. Boger RH, Skamira C, Bode-Boger SM, Brabant G von zur Muhlen A, Frolich JC. Nitric oxide may mediate the haemodynamic effects of recombinant growth hormone in patients with acquired growth hormone deficiency. J Clin Invest 1996;98:2706-13.
7. Johansson JO, Fowelin JI, Landin K, Larger J, Bengtsson BA. Growth hormone deficient adults are insulin resistant. Metabolism 1995;44:1126-9.
8. Johansson JO, Landin K, Tengborn L, Rosen T, Bengtsson BA. High fibrinogen and plasminogen activator inhibitor (PAI-1) activity in growth hormone-deficient adults. Atheroscler Thromb 1994;14:434-7.
9. Serri O, St-Jacques P, Sartippour M, Renier G. Alterations of monocyte function in patient with growth hormone deficiency: Effect of substitutive therapy. J Clin Endocrinol Metab 1999;84:58-63.
10. Sesmilo G, Biller BM, Llevadot J, et al. Effects of growth hormone administration on inflammatory and other cardiovascular risk markers in men with growth hormone deficiency. A randomized, controlled clinical trial. Ann Intern Med 2000;133:111-22.
11. Serri O, Li L, Maingrette F., Jaffry N, Renier G. Enhanced lipoprotein lipase secretion and foam cell formation by macrophages of patients with growth hormone deficiency : possible contribution to increased risk of atherogenesis? J Clin Endocrinol Metab 2004;89:979-85.
12. Ezzat S, Fear S, Gaillard R-C, Gayle C, Landy H, Marcovitz S, Mattioni T, Nussey S, Rees A, Svanberg E. Circulating IGF-I levels in monitoring and predicting efficacy during long-term GH treatment of GH-deficient adults. Eur J Endocrinol 2003;149:499-509.
13. Bates AS, Van't Hoff W, Jones PJ, Clayton RN. The effect of hypopituitarism on life expectancy. J Clin Endocrinol Metab 1996;81:1169-72.
14. Bulow B, Hagmar L, Mikoczy Z, Nordstrom CH, Erfurth EM. Increased cerebrovascular mortality in patients with hypopituitarism. J Clin Endocrinol Metab 1997;46:75-81.
15. Hoffman DM, O'Sullivan AJ, Baxter RC, Ho KKY, Ken KY. Diagnosis of growth-hormone deficiency in adults. Lancet 1994;343:1064-8.
16. Korbonits M, Besser M: Diagnosis of growth hormone deficiency in adults. Horm Res 1996;46:174-82.
17. Booth GL, Zahedi A, Ezzat S. Evaluation of Normal Pituitary Function. In Melmed S (ed.): The Pituitary. 2nd Edition. Blackwell, Boston, 2002;709-26.
18. Juul A, Kastrup KW, Pedersen SA, Skakkebæk NE. Growth hormone (GH) provocative retesting of 108 young adults with childhood-onset GH deficiency and the diagnostic value of insulin-like growth I (IGF-I) and IGF-binding protein-3. J Clin Endocrinol Metab 1997;82:1195-201.
19. Frasier SD, Hilburn JM, Smith FG Jr. Effect of adolescence on the serum growth hormone response to hypoglycemia. Journal of Pediatrics 1970;77:465-7.
20. Muggeo M, Fedele D, Tiengo A, Molinari M, Crepaldi G. Human growth hormone and cortisol response to insulin stimulation in aging. J Gerontol 1975;30:546-51.
21. Slover RH, Klingensmith GJ, Gotlin RW, Radcliff J. A comparison of clonidine and standard provocative agents of growth hormone. AJDC 1984;138:314-7.
22. Laron Z, Gil-Ad I, Topper E, Kaufman H, Josefsberg Z. Low oral dose of Clonidine: An effective screening test for growth hormone deficiency. Acta Paediatr Scand 1982;71:847-8.
23. Porter BA, Rosenfield RL, Lawrence AM. The Levodopa test of growth hormone reserve in children. AJDC 1973;126:589-92.
24. Toogood AA, O'Neill PA, Shalet SM. Beyond the somatopause: Growth hormone deficiency in adults over the age of 60 years. J Clin Endocrinol Metab 1996;81:460-5.
25. Schriock EA, Lustig RH, Rosenthal SM, Kaplan SL, Grumbach MM. Effect of growth hormone (GH)-releasing hormone (GHRH) on plasma GH in relation to magnitude and duration of GH deficiency in 26 children and adults with isolated GH deficiency or multiple pituitary hormone deficiencies: Evidence for hypothalamic GRH deficiency. J Clin Endocrinol Metab 1984;58:1043-9.
26. Taxis K, and Schneeweiss S. Frequency and predictors of drug therapy interruptions after hospital discharge under physician drug budgets in Germany. International Journal of Clinical Pharmacology Therapeutics 2003;41:77-82.
27. Woodhouse LJ et al. Measures of submaximal aerobic performance evaluate and predict functional response to growth hormone (GH) treatment in GH-deficient adults. J Clin Endocrinol Metab 1999;84:4570-7.
28. Johannsson et al. Growth Hormone treatment of abdominally obese men reduces abdominal fat mass, improves glucose and lipoprotein metabolism, and reduces diastolic blood pressure. J Clin Endocrinol Metab March 1997;82:727-34
29. Mauras N et al. Insulin-like growth factor I and growth hormone (GH) treatment in GH-deficient humans: Differential effects on protein, glucose, lipid, and calcium metabolism. J Clin Endocrinol Metab 2000;85:1686-94.
30. Hoffman AR et al. Growth Hormone (GH) replacement therapy in adult-onset GH deficiency: effects on body composition in men and women in a double-blind, randomized, placebo-controlled trial. J Clin Endocrinol Metab 2004;89:2048-56.
31. Burman P et al. Quality of life in adults with growth hormone (GH) deficiency: response to treatment with recombinant human GH in a placebo-controlled 21-month trial. J Clin Endocrinol Metab 1995;80:3585-90.
32. Baum HBA et al. Effects of physiologic growth hormone therapy on bone density and body composition in subjects with adult-onset growth hormone deficiency. Ann Intern Med 1996;125:883-90.
33. Johannsson G et al. Two years of growth hormone (GH) treatment increases bone mineral content and density in hypopituitary subjects with adult-onset GH deficiency. J Clin Endocrinol Metab 1996;81:2865-73.